Skip to main content

Advertisement

Table 2 Univariate analyses of factors potentially associated with detection of CBD stones

From: Diagnostic yield of endoscopic ultrasonography in patients with intermediate or high likelihood of choledocholithiasis: a retrospective study from one university-based endoscopy center

  No CBD stone detected (n = 65) CBD stone detected (n = 28) p value
Mean (±SD) age (years) 58.85 (±16.09) 65.26 (±13.76) 0.06
Mean (±SD) alkaline phosphatase level (U/mL) 147.40 (±127.55) 226.30 (±192.64) 0.02*
Mean (±SD) total bilirubin level (mg/dL) 3.19 (±5.20) 2.57 (±2.33) 0.54
Mean (±SD) SGOT level (U/L) 215.13 (±176.86) 215.13 (±250.75) 0.13
Mean (±SD) SGPT level (U/L) 137.07 (±210.94) 198.65 (±184.04) 0.17
Clinical classification    0.06
Intermediate likelihood (n = 49) 38 11  
High likelihood (n = 44) 27 17  
Dilated CBD on transabdominal    
ultrasonography (n = 26) 5 21 0.48
Mean (±SD) time interval (days) 38.95 (±62.77) 33.23 (±42.24) 0.64
EUS performed within 7 days (n) 14 14 0.02*
  1. CBD common bile duct, EUS endoscopic ultrasonography, ERCP endoscopic retrograde cholangiopancreatography, SGOT serum glutamic-oxaloacetic transaminase, SGPT serum glutamic-pyruvic transaminase.